Bioceres Crop Solutions Corp Stock Price, News & Analysis

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) has finalized capital commitments related to its merger with Marrone Bio Innovations, issuing secured guaranteed convertible notes worth $55 million with a 4-year maturity at an interest rate of 9%. The proceeds will address financial obligations of ProFarm Group and support merger synergies. Additionally, Bioceres issued new secured notes for $24.4 million to cover remaining convertible notes from 2020. Both note issuances aim to enhance operational efficiency while maintaining a strong financial structure.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) will participate in the Canaccord Genuity 42nd Annual Growth Conference from August 8-11, 2022, in Boston, MA. Key executives, including Chairman Federico Trucco and CFO Enrique Lopez Lecube, will conduct one-on-one meetings to discuss the company’s recent acquisition of Marrone Bio Innovations and HB4® Wheat and Soy approvals on August 10-11. Bioceres will also present on August 11 from 11:00-11:25 AM ET. For more details, visit the conference website or contact investor relations.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) announced the successful integration of Marrone Bio Innovations, Inc. (NASDAQ: MBII), valued at approximately $207 million. The merger, approved with 99.74% of votes on July 8, 2022, enhances Bioceres's position in sustainable agricultural solutions. MBI will operate as ProFarm, integrating its operational capabilities while leveraging expertise from former key employees. Changes in leadership include the addition of MBI directors to Bioceres's Board. This acquisition aims to foster a carbon-neutral agricultural landscape through innovative biological solutions.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) announced the FDA's conclusion of its evaluation of HB4® Wheat, indicating no further safety questions. This marks a crucial step toward commercialization in the U.S., pending USDA approval. The United States ranks fifth in wheat production, with HB4® Wheat already authorized in Argentina and recent approvals in Brazil, Colombia, Australia, and New Zealand. The HB4® technology significantly boosts wheat yields by 20% in water-limited conditions, promoting sustainable agricultural practices.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) will participate in the ROTH 8th Annual London Conference from June 21-23, 2022, held at the InterContinental London Park Lane. CEO Federico Trucco and CFO Enrique Lopez Lecube are set to engage in one-on-one meetings to discuss the company’s fiscal Q3 2022 financial results and its merger agreement with Marrone Bio Innovations. For details about the conference or to connect with the company, interested parties can contact ROTH representatives or reach out via email.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) reported a strong fiscal third quarter 2022, with comparable revenues rising 72% to $60.1 million. The company achieved key regulatory approval for HB4 Soy in China, enabling commercialization in multiple countries. EBITDA targets for HB4 Soy in FY25 are projected at $20-25 million. Additionally, HB4 Wheat received approval in Colombia, Australia, and New Zealand, with expected revenues of $10-12 million for the upcoming planting season. The merger with Marrone Bio Innovations is set to close in Q1 FY23.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is set to discuss its fiscal Q3 2022 results on May 12, 2022, at 8:30 a.m. EDT. The call will be hosted by CEO Federico Trucco, CFO Enrique Lopez Lecube, and Head of Investor Relations Rodrigo Krause. It will include a presentation and a Q&A session. The company aims to support the transition towards carbon-neutral agriculture with its biotech solutions focused on crop productivity. A replay will be available until May 17, 2022.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) announced that China’s Ministry of Agriculture has approved the import and use of soybeans produced with its HB4® drought-tolerant technology. This clearance allows for the unrestricted commercialization of HB4® soy, which has already been approved in Argentina, the U.S., Canada, Brazil, and Paraguay, covering approximately 85% of the global soybean trade. Bioceres plans to elaborate on the impact of this approval in its financial results conference call on May 12 at 8:30 am EDT.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) and Marrone Bio Innovations, Inc. (NASDAQ: MBII) have announced a definitive agreement to merge in an all-stock transaction valued at approximately $236 million. Each share of MBI will convert to Bioceres shares at a ratio of 0.088. The merger aims to create a global leader in sustainable agricultural solutions, leveraging Bioceres' bionutrition expertise and MBI's biological crop protection portfolio. The deal is expected to close in Q3 2022, pending shareholder and regulatory approvals.